Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
June 03 2024 - 4:05PM
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell
reprogramming company advancing a diverse pipeline of cell
therapies for patients with solid tumors, today announced that
members of its senior management team will participate in the
Goldman Sachs 45th Annual Global Healthcare Conference on Monday,
June 10 at 4:00 pm ET.
A live webcast of the presentation can be accessed through the
Investors section of the Company's website at www.lyell.com.
Following the live presentation, a replay of the webcast will be
available on the Company's website following the presentation
date.
About Lyell Immunopharma,
Inc.
Lyell is a clinical-stage T-cell reprogramming
company advancing a diverse pipeline of cell therapies for patients
with solid tumors. Lyell is currently enrolling a Phase 1 clinical
trial evaluating a ROR1-targeted CAR T-cell therapy in patients
with relapsed refractory triple-negative breast cancer (TNBC) and
non-small cell lung cancer (NSCLC) and a second Phase 1 clinical
trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL)
in patients with advanced melanoma, NSCLC and colorectal cancer.
The technologies powering its product candidates are designed to
address barriers that limit consistent and long-lasting responses
to cell therapy for solid tumors: T-cell exhaustion and lack of
durable stemness, which includes the ability to persist and
self-renew to drive durable tumor cytotoxicity. Lyell is applying
its proprietary ex vivo genetic and epigenetic reprogramming
technologies to address these barriers in order to develop new
medicines with improved durable clinical outcomes. Lyell is based
in South San Francisco, California with facilities in Seattle and
Bothell, Washington. To learn more, please
visit www.lyell.com.
Contact:Ellen RoseSenior Vice
President, Communications and Investor Relationserose@lyell.com
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
From Oct 2023 to Oct 2024